Real‐world outcomes of aflibercept 8 mg in patients previously treated for neovascular age‐related macular degeneration
Switching to aflibercept 8 mg led to stable vision, significant anatomical improvements, extended treatment intervals and a favourable short-term safety profile. Longer follow-up is warranted.
Authors
- Marita Andersson Grönlund (ORCID: https://orcid.org/0000-0002-6298-360X)
- Sofia Töyrä Silfverswärd (ORCID: https://orcid.org/0000-0002-6641-2759)
- Madeleine Zetterberg (ORCID: https://orcid.org/0000-0001-8230-0741)
- Martin Breimer
- Imadeddin Abu Ishkheidem
- Esra Inci
Institutions
- Örebro University (SE)
- Sahlgrenska University Hospital (SE)
- Region Västra Götaland (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Acta Ophthalmologica
- Published
- 2025-09-08
- DOI
- https://doi.org/10.1111/aos.17590
- Citations
- 2
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.41